tiprankstipranks
Trending News
More News >
Cartesian Therapeutics (RNAC)
NASDAQ:RNAC
Advertisement

Cartesian Therapeutics (RNAC) AI Stock Analysis

Compare
1,116 Followers

Top Page

RNAC

Cartesian Therapeutics

(NASDAQ:RNAC)

Select Model
Select Model
Select Model
Underperform 39 (OpenAI - 4o)
Rating:39Underperform
Price Target:
$9.00
▼(-2.81% Downside)
The overall stock score of 39 reflects significant financial challenges, including declining revenues, negative equity, and weak cash flows. Technical indicators show a bearish trend, and the valuation metrics highlight high risk due to unprofitability. The lack of earnings call data and corporate events further limits positive outlooks.
Positive Factors
Innovative RNA Platform
The proprietary RNA platform positions Cartesian Therapeutics to develop novel therapeutics, potentially addressing unmet medical needs in neurology and oncology, which can drive long-term growth and competitive advantage.
Revenue from Partnerships
Strategic partnerships provide a steady revenue stream through funding, milestone payments, and potential royalties, supporting R&D and reducing financial risk associated with drug development.
High Gross Profit Margin
A high gross profit margin indicates efficient production processes and pricing power, which can be leveraged to improve overall profitability as operational efficiencies are realized.
Negative Factors
Negative Equity
Negative equity suggests financial instability and limits the company's ability to raise capital, potentially hindering growth and increasing vulnerability to economic downturns.
Declining Revenue
Significant revenue decline indicates challenges in market penetration and product adoption, which could impact long-term sustainability unless reversed through strategic initiatives.
Negative Operating Cash Flow
Negative operating cash flow reflects ongoing financial strain, limiting the company's ability to invest in growth opportunities and potentially necessitating external financing.

Cartesian Therapeutics (RNAC) vs. SPDR S&P 500 ETF (SPY)

Cartesian Therapeutics Business Overview & Revenue Model

Company DescriptionSelecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.
How the Company Makes MoneyCartesian Therapeutics generates revenue primarily through partnerships and collaborations with pharmaceutical companies and research institutions. These partnerships often involve funding for research and development activities, as well as milestone payments associated with the advancement of therapeutic candidates through clinical trials. Additionally, the company may receive royalties on future sales of products developed through these collaborations. The potential for licensing agreements also represents a significant revenue stream, as Cartesian Therapeutics seeks to monetize its proprietary technologies and therapeutic candidates.

Cartesian Therapeutics Financial Statement Overview

Summary
Cartesian Therapeutics is facing significant financial challenges. The income statement reflects declining revenues and high operational losses, while the balance sheet shows negative equity, suggesting financial instability. Cash flow statements highlight cash outflows and dependency on external financing, raising concerns about the company's long-term sustainability.
Income Statement
25
Negative
Cartesian Therapeutics shows a concerning trend in profitability, with a negative TTM net profit margin of -112.1% and a declining revenue trend. The gross profit margin remains high at 99.4% in the TTM, but the company struggles with negative EBIT and EBITDA margins, indicating operational inefficiencies and high costs relative to revenue.
Balance Sheet
30
Negative
The company's balance sheet is weak, highlighted by a negative stockholders' equity of -$21.79 million in the TTM, indicating financial distress. The debt-to-equity ratio cannot be calculated due to negative equity, and the equity ratio is also negative. These factors point to potential liquidity issues and high leverage risk, despite having substantial cash reserves.
Cash Flow
40
Negative
Cartesian Therapeutics has a negative free cash flow in the TTM of -$40.43 million, indicating cash outflow concerns. The operating cash flow to net income ratio shows operational cash drain, reflecting inefficiencies. However, significant financing cash flow suggests reliance on external funding to sustain operations.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue1.03M38.91M26.00M110.78M85.08M16.60M
Gross Profit1.03M38.91M24.45M108.74M85.08M16.60M
EBITDA-75.92M-77.14M-235.06M39.84M-5.16M-65.59M
Net Income-36.26M-77.42M-219.71M35.38M-25.69M-68.88M
Balance Sheet
Total Assets388.89M435.02M305.05M165.89M159.88M165.44M
Cash, Cash Equivalents and Short-Term Investments160.32M212.61M76.91M134.60M128.06M138.69M
Total Debt13.35M13.98M10.96M37.92M35.28M35.35M
Total Liabilities391.42M441.82M745.23M72.06M137.36M183.44M
Stockholders Equity-2.53M-6.80M-440.18M93.83M22.52M-18.01M
Cash Flow
Free Cash Flow-44.51M-32.77M-51.37M-32.83M-61.47M34.07M
Operating Cash Flow-33.94M-23.67M-51.16M-31.63M-60.38M34.88M
Investing Cash Flow-10.22M-8.74M34.61M-15.00M-17.14M-741.00K
Financing Cash Flow117.31M168.43M-13.14M39.22M52.90M14.43M

Cartesian Therapeutics Technical Analysis

Technical Analysis Sentiment
Negative
Last Price9.26
Price Trends
50DMA
11.01
Negative
100DMA
10.83
Negative
200DMA
13.74
Negative
Market Momentum
MACD
-0.37
Negative
RSI
41.14
Neutral
STOCH
35.22
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RNAC, the sentiment is Negative. The current price of 9.26 is below the 20-day moving average (MA) of 9.87, below the 50-day MA of 11.01, and below the 200-day MA of 13.74, indicating a bearish trend. The MACD of -0.37 indicates Negative momentum. The RSI at 41.14 is Neutral, neither overbought nor oversold. The STOCH value of 35.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RNAC.

Cartesian Therapeutics Risk Analysis

Cartesian Therapeutics disclosed 46 risk factors in its most recent earnings report. Cartesian Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Cartesian Therapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
58
Neutral
602.02M-9.97-33.59%-26.88%13.41%
43
Neutral
382.66M-3.15-9.14%
41
Neutral
735.44M-4.1839.03%
40
Underperform
82.36M-1.05-91.44%-100.00%11.89%
39
Underperform
$240.78M-938.38%38.82%-645.78%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
RNAC
Cartesian Therapeutics
9.26
-6.86
-42.56%
ORKA
Oruka Therapeutics
15.20
-9.31
-37.98%
ARCT
Arcturus Therapeutics
22.17
-1.04
-4.48%
ATYR
aTyr Pharma
0.84
-0.92
-52.27%
VERV
Verve Therapeutics
11.13
6.29
129.96%
AURA
Aura Biosciences Inc
6.16
-2.75
-30.86%

Cartesian Therapeutics Corporate Events

Executive/Board ChangesShareholder Meetings
Cartesian Therapeutics Holds Annual Stockholders Meeting
Neutral
Jun 16, 2025

On June 13, 2025, Cartesian Therapeutics, Inc. held its Annual Meeting of Stockholders, where 21,868,804 shares were represented, accounting for approximately 84.31% of the company’s outstanding stock. During the meeting, three Class III Directors were elected to serve until the 2028 Annual Meeting, the compensation of the company’s named executive officers was approved on a non-binding basis, and Ernst & Young LLP was ratified as the independent registered public accounting firm for the year ending December 31, 2025.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 20, 2025